Lower Side Effects of Milnacipran Than Paroxetine in the Treatment of Major Depression Disorder among Han Chinese in Taiwan

Ting-Ting Chang；Chhian-Hūi Lêng；Jo Yung-Wei Wu；Sheng-Yu Lee；Yu-Shan Wang；Yi-Chyan Chen；Ru-Band Lu

milnacipran ； paroxetine ； major depression ； efficacy ； side effect

The Chinese Journal of Physiology

51卷6期（2008 / 12 / 01）

387 - 393

英文

Milnacipran is a dual-action antidepressant which inhibits both serotonin and norepinephrine reuptake. To our knowledge, it has limited affinity for most monoamine neurotransmitter receptors. With limited pharmacokinetic interaction with the cytochrome 450 system, milnacipran may have a low risk in drug interaction. The present study compares milnacipran with paroxetine, a selective serotonin reuptake inhibitor (SSRI) and which has been used clinically for years to evaluate the efficacy, patient tolerance, and side effects in the treatment of major depression. The study took place in two medical centers located in Northern and Southern Taiwan. Six-three participant who met the Diagnostic and Statistical Manual of Mental Disorder 4th edition (DSM-IV) criteria for a major depressive disorder and a total Hamilton Depression Rating Scale (HAM-D) score ≥ 16 on the 17 item scale, were recruited. Participants first received either 100 mg/day of milnacipran (33 participants) or 20 mg/day of paroxetine (30 participants), and were then assessed with HAM-D and clinical global impression scale (CGI) for severity of the illness and global improvement, at the beginning and the end of the first, second, fourth, and eighth weeks of the drug treatment. Thirty-eight patients with major depressive disorder completed the study. No statistically significant differences were observed between the two groups in the reduction of HAM-D and CGI scores. However, side effects such as headache and tremor in the first week, psychomotor retardation and difficulty in concentration in the fourth week, and psychomotor retardation in the eighth week of treatment were significantly lower in the milnacipran group, as compared to that of the paroxetine group. We concluded that milnacipran and paroxetine had similar clinical effectiveness during the eight-week treatment of major depressive disorder. Further investigation is needed to examine the clinical suitability of this drug for patients with liver impairments and for elderly patients suffering from major depression.

1. Bockting, C.L.,Spinhoven, P.,Koeter, M.W.,Wouters, L.F.,Schene, A.H.(2006).Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study.J. Clin. Psychiatry.,67,747-755.
2. Bourin, M.,Chue, P.,Guillon, Y.(2001).Paroxetine: A review.CNS Drug Rev.,7,25-47.
3. Delini-Stula, A.(2000).Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake.Hum. Psychopharmacol.,15,255-260.
4. Hamilton, M.(1960).A rating scale for depression.J. Neurol. Neurosurg. Psychiatry,23,56-62.
5. Hiemke, C.(1994).Paroxetine: pharmacokinetics and pharmacodynamics.Fortschr. Neurol. Psychiatr.,62,2-8.
6. Khun, R.(1957).Uher die Behandlung depressiver Zustande mit einen Ominodibenzyl-deriva G22355.Schiweizerische Medizinische Wochenschrift,87,1135-1149.
7. Ko, H.C.,Lu, R.B.,Shiah, I.S.,Heang, C.C.(1997).Plasma free 3-methoxy-4-hydrophenyl-glycol predicts response to fluoxetine.Biol. Psychiatry,41,774-781.
8. Kolb, L.C.(1997).Modern Clinical Psychiatric.Philadelphia:W. B. Sauders Co..
9. Lecrubiter, Y.(1997).Milnacipran: The clinical properties of a selective serotonin and noradrenaline reuptake inhibitor SNRI.Hum. Psychopharmacol.,12,127-134.
10. Lin, K.M.,Finder, E.(1983).Neuroleptic dosage for Asians.Am. J. Psychiatry,140,490-491.
11. Lopez-Ibor, J.,Guelfi, J.D.,Pletan, Y.,Tournoux, A.,Prost, J.F.(1996).Milnacipran and selective serotonin reuptake inhibitors in major depression.Int. Clin. Psychopharmacol.,11,41-46.
12. Lu, R.B.(1992).Depression.Cont. Med. Educ.,2,708-713.
13. Lu, R.B.,Ko, H.C.,Hwang, C.C.,Lin, Y.T.(1991).Comparison of the clinical efficacy and safety of fluoxetine and imipramine in major depressive disorder.J. Am. Med. Assoc. Southeast Asia,7,41-45.
14. Montgomery, S.A.,Prost, J.F.,Solles, A.,Briley, M.(1996).Efficacy and tolerability of milnacipran: an overview.Int. Clin. Psychopharmacol.,11,47-51.
15. Montgomery, S.A.,Robters, A.,Mongtomery, D.B.(1994).Depression: a long-term illness and its treatment.Proceedings from a Lundbeck Symposiom held in Washington, DC. In: The 19th CNIP Congress
16. Morishita, S.,Arita, S.(2003).The clinical use of milnacipran for depression.Eur. Psychiatry.,18,34-35.
17. Morishita, S.,Arita, S.(2003).Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.Hum. Psychopharmacol.,18,479-482.
18. Morishita, S.,Arita, S.(2004).Different effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.Hum. Psychopharmacol.,19,405-408.
19. Nierenberg, A.A.,Gray, S.M.,Grandin, L.D.(2001).Mood disorders and suicide.J. Clin. Psychiatry.,62,27-30.
20. Owens, M.J.,Knight, D.L.,Nemeroff, C.B.(2000).Paroxetine binding to the rat norepinephrine transporter in vivo.Biol. Psychiatry,47,842-845.
21. Preskorn, S.H.(2004).Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor.J. Psychiatr. Pract.,10,119-126.
22. Puech, A.,Montgomery, S.A.,Prost, J.F.,Solles, A.,Briley, M.(1997).Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.Int. Clin. Psychopharmacol.,12,99-108.
23. Puozzo, C.,Albin, H.,Vincon, G.,Deprez, D.,Raymond, J.M.,Amouretti, M.(1998).Pharmacokinetics of milnacipran in liver impairment.Eur. J. Drug. Metab. Pharmacokinet.,23,273-279.
24. Puozzo, C.,Leonard, B.E.(1996).Pharmacokinetics of milnacipran in comparison with other antidepressants.Int. Clin. Psychopharmacol.,11,15-27.
25. Rudorfer, M.V.,Lane, E.,Chang, W.H.,Zhang, M.,Potter, W.Z.(1984).Desipramine pharmacokinetics in Chinese and Caucasian volunteers.Brit. J. Clin. Pharmacol.,17,433-440.
26. Sadock, B.J.,Sadock, V.A.(1994).Synopsis of Psychiatry.Baltimore:Willams and Wilkins.
27. Sechter, D.,Vandel, P.,Weiller, E.,Pezous, N.,Cabance, F.,Tournoux, A.(2004).A comparative study of milnacipran and paroxetine in out-patients with major depression.J. Affect. Disord.,83,233-236.
28. Sheehan, D.V.,Lecrubier, Y.,Sheehan, K.H.,Amorim, P.,Janavs, J.,Weiller, E.,Hergueta, T.,Baker, R.,Dunbar, G.C.(1998).The Mini-International Neuropsychiatric Interview M.I.N.I.: the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.J. Clin. Psychiatry.,59,22-33.
29. Shinji, S.,Yuriko, Y.,Yasushi, T.,Hitoshi, O.,Takashi, A.(2006).Efficacy of milnacipran on cognitive dysfunction with post-storke depression: Preliminary open-label study.Psychiatry Clin. Neurosci.,60,584-589.
30. Shopsin, B.,Waters, B.(1980).The pharmacotherapy of major depression syndrome. Part I: Treatment of acute depression.Psychosom. Med.,21,554-556.
31. Stahl, S.M.,Grady, M.M.,Moret, C.,Briley, M.(2005).SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.CNS Spectr.,10,732-747.
32. Sugrue, M.F.(1981).Current concepts of the mechanisms of antidepressant drugs.Pharmacol. Ser.,13,219-247.
33. Thase, M.E.,Entsuah, A.R.,Rudolph, R.L.(2001).Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.Brit. J. Psychiatry.,178,234-241.
34. Tignol, J.,Pujol-Domenech, J.,Chartres, J.P.,L'eger, J.M.,Pl`etan, Y.,Tonelli, I.(1998).Double blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.Acta. Psych. Scand.,97,157-165.
35. Yazici, O.,Aricioglu, F.,Gurvit, G.,Ucok, A.,Tastaban, Y.,Canberk, O.,Ozguroglu, M.,Durat, T.,Sahin, D.(1993).Noradrenergic and serotoninergic depression.J. Affective. Disord.,27,123-129.
36. Yeh, C.B.,Ko, H.C.,Lu, R.B.(1999).Comparison of the clinical efficacy and safety of venlafaxine and imipramine in major depressive disorder.Taiwanese J. Psychiatry,13,44-53.

1. 林式穀(2016)。Clinical Trials in Psychiatry: Focusing on Antipsychotic Development。臺灣精神醫學，30(2)，91-100+ii。